Coronamellitus: An Infecto-Metabolic Pandemic
DOI:
https://doi.org/10.24950/O/119/20/3/2020Keywords:
Coronavirus Infections, COVID-19, Diabetes MellitusAbstract
Introduction: There are considerable differences in mortality due to SARS-CoV-2 infection. Advanced age and comorbidities, such as diabetes mellitus, have been associated with a worse prognosis. The aim of this study was to assess the impact of diabetes and metabolic control on Emergency Department (ED) admission in patients with COVID-19 with hospitalization criteria.
Methods: Clinical and laboratorial features were assessed through ED clinical file consultation of patients hospitalized with COVID-19 at CHTV. The data included inflammatory and metabolic profile, personal history and chronic medication.
Results: Eighty nine patients were included, 38.2% women and 61.8% men, with a mean age of 73.23 years ± 16.26. 29.2% patients had a previous diabetes diagnosis, 53.4% hypertension and 29.5% cardiac insufficiency. The overall mortality was 14.6%, 7.86% of the patients were admitted to the iIntensive Care Unit and there were no significant differences between the groups (diabetic versus non-diabetic). The average HbA1C was 6.96% and there was a positive and significant correlation between the blood glucose values and lactate, C-reactive protein and leukocyte values.
Conclusion: Higher blood glucose levels at ED admission appear to be associated with more severe inflammatory states and may also explain some of the variance in lactate and leukocyte values. The diabetic population had good metabolic control, which may clarify the absence of significant differences in severity and mortality between groups.
Downloads
References
Pal R, Bhansali A. COVID-19, diabetes mellitus and ACE2: the conundrum. Diabetes Res Clin Pract. 2020;162:108132. doi: 10.1016/j.diabres.2020.108132.
Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr Clin Res Rev. 2020;14:303e10.
Huang I, Lim MA, Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia e a systematic review, meta-analysis, and meta-regression. Diabetes Metab Syndr Clin Res Rev. 2020;14:395e403.
Guan W, Liang W, Zhao Y, Liang H, Chen Z, Li Y, et al. Comorbidity and its impact on 1590 patients with covid-19 in China: a nationwide analysis. Eur Respir J. 2020:2000547.
Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020 (in press). doi: 10.1002/dmrr.3319
Kulcsar KA, Coleman CM, Beck SE, Frieman MB. Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection. JCI Insight. 2019;4. doi:10.1172/jci.insight.131774.
Angelidi AM, Belanger MJ, Mantzoros CS. COVID-19 and diabetes mellitus: what we know, how our patients should be treated now, and what should happen next. Metab Clin Exp. 2020 (in press). doi:10.1016/j.metabol.2020.154245.
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033e4. doi:10.1016/S0140-6736(20)30628-0.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395: 497e506. doi:10.1016/S0140-6736(20)30183-5.
Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018;61:2461-98. doi: 10.1007/s00125-018-4729-5.
Iacobellis G. COVID-19 and diabetes: can DPP4inhibition play a role? Diabetes Res Clin Pract. 2020;162:108125. doi:10.1016/j.diabres.2020.108125.
Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2008:CD006739. doi: 10.1002/14651858.CD006739.pub2.
Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. J Am Med Assoc. 2007;298: 194e206. doi:10.1001/jama.298.2.194.
Kumar A, Arora A, Sharma P, Anikhindi SA, Bansal N, Singla V, et al. Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. Diabetes Metab Syndr. 2020;14:535-45. doi: 10.1016/j.
dsx.2020.04.044.
Critchley JA, Carey IM, Harris T, DeWilde S, Hosking FJ, Cook DG. Glycemic control and risk of infections among people with type 1 or type 2 diabetes in a large primary care cohort study. Diabetes Care. 2018;41:2127e35. doi:10.2337/dc18-0287.
Mor A, Dekkers OM, Nielsen JS, Beck-Nielsen H, Sørensen HT, Thomsen RW. Impact of glycemic control on risk of infections in patients with type 2 diabetes: a population-based cohort study. Am J Epidemiol.
;186:227e36. doi: 10.1093/aje/kwx049.
Cohen J. Statistical power analysis for the behavioral sciences. Hillsdale: Erlbaum; 1988.
Pape E, Lopes P, Escarigo C, Nunes A, Ramalho S, Nortadas R. Apresentação do estudo DIAMEDINT 2, 24º Congresso Nacional de Medicina Interna, Junho 2018.
Pal R, Bhadada SK. COVID-19 and diabetes mellitus: An unholy interaction of two pandemics [published online ahead of print, 2020 May 6]. Diabetes Metab Syndr. 2020;14:513-7. doi:10.1016/j.dsx.2020.04.049
Coronavirus disease 2019 (COVID-19) situation report e 98. [Accessed April 28, 2020]. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200427-sitrep-98-covid-19.pdf?sfvrsn¼90323472_4
Pal R, Bhadada SK. COVID-19 and non-communicable diseases. Postgrad Med. 2020;162:108132. doi: postgradmedj-2020-137742.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2023 Medicina Interna
Open Access
